Wednesday, September 2, 2026
Vertex closes $10 billion Crinetics acquisition
Vertex Pharmaceuticals completed its acquisition of Crinetics Pharmaceuticals on September 1, 2026, a deal worth about $10.0 billion in total equity value (roughly $8.8 billion net of acquired cash), after clearing shareholder and antitrust approvals. The deal adds the marketed acromegaly drug Palsonify (paltusotine) and pipeline candidate atumelnant, and Vertex announced an expanded executive leadership team, naming Jonathan Poole EVP and Chief Financial Officer and adding Jasper van Grunsven as EVP, Chief Pain and New Product Planning Officer, to support the new endocrine-disease business.
/ Sources
/ About this story
Compiled by Venture Atlas from the sources above, using automated AI-assisted research. This is a summary of reporting published elsewhere, not original reporting - follow the source links for the full account. See our editorial standards.
Something wrong here? Email flightatlas.contact@gmail.com and we will fix it.
/ Related
- Crinetics shareholders approve Vertex's $10 billion buyoutTuesday, September 1, 2026
- Court clears Lupin's generic Kalydeco in Vertex patent fightThursday, August 27, 2026
- Rival's cystic fibrosis drug fails, Vertex shares gainThursday, August 13, 2026
- Vertex tops Q2 estimates, raises 2026 revenue guidanceTuesday, August 4, 2026